Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bria-IMT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bria-IMT overview

Bria-IMT (BriaVax) is under development for the treatment of advanced metastatic breast cancer, triple-negative breast cancer, HER2+ breast cancer and HER2- breast cancer. The vaccine candidate  is administered intradermally. The vaccine candidate is a HER2/neu-positive allogeneic (non-self) breast cancer cell line (SV-BR-1) transfected with the GM-CSF gene to produce the naturally occurring cytokine GM-CSF.

BriaCell Therapeutics overview

BriaCell Therapeutics is a healthcare services provider company. The company develops novel immunotherapies cutting-edge technology to fight cancer. Its services include BRIA-IMT technology, BRIA-OTS technology, PKCd technology, patents technology, mechanism of action technology, and clinical trials and technology services. BriaCell Therapeutics also develops diagnostic testing products and technology, business technology development, proprietary technology, and potential combination treatment options to treat various cancer indications. The company Bria-IMT a targeted immunotherapy being developed for the treatment of breast cancer and genetically engineered human breast cancer cell line with features of immune cells and clinically applied as a targeted immunotherapy. It has operations in the US and Canada. BriaCell Therapeutics is headquartered in West Vancouver, British Columbia, Canada.

For a complete picture of Bria-IMT’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.